摘要
IgA肾病(IgA nephropathy,IgAN)是最常见的原发性肾小球肾炎之一,但目前的治疗手段相对较少,且治疗效果有限,缺乏对因性治疗。近年来,许多研究针对其发病机制中重要的信号通路及关键分子进行不断的探索,其中部分初期研究结果显示一些药物有较好的临床效果。本综述基于IgAN的发病机制,介绍目前国内外在研治疗IgAN的新型药物,旨在为IgAN的治疗提供参考。
IgA nephropathy(IgAN)is one of the most common primary glomerulonephritis.Few therapeutic options are currently available and the effectiveness is rather limited due to a lack of etiologic treatment.In recent years,many studies have focused upon the important signaling pathways and key molecules in the pathogenesis of IgAN.New drugs with benefits for IgAN have been developed and some show preliminary clinical promises.Based upon the pathogenesis of IgAN,this review summarized the latest agents for IgAN at home and abroad,aiming to provide more reference for the treatment of IgAN.
作者
徐丽梨
王伟铭
Xu Li-li;Wang Wei-ming(Department of Nephrology,Ruijing Hospital North,Shanghai Jiao Tong University School of Medicine,Shanghai 201800,China)
出处
《临床肾脏病杂志》
2023年第1期70-74,共5页
Journal Of Clinical Nephrology
基金
瑞金医院北部重点培育学科-肾脏内科(2017XK08)。
关键词
IGA肾病
发病机制
治疗
IgA nephropathy
Pathogenesis
Therapeutic
